Chemotherapy in Medical Technology

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that Vectibix((R)) (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with F...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

CALGARY, July 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ('Oncolytics') reported today that Dr. Shizuko Sei et al. published the results of their work examining reovirus and chemotherapy against human non-small cell lung cancer (NSCLC). The paper, entitled "Syn...

Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells

Therapy targets folate receptors found on cancer cells otherwise resistant to standard chemo ZION, Ill., June 17 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, a leading provider of innovative cancer care for patients living wi...

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

Overview of 11 peer review publications presented in 'Future Oncology' SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies wit...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

Abstract # 6053 ORLANDO, Fla., June 1 /PRNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data demonstrating the feasibility of long-term, low-dose adjuvant chemotherapy, which resulted in fewer tumor recurrences and cancer metastases in patients wit...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

- Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone - MADRID, May 30 /PRNewswire/ -- The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced toda...

Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

HUNTINGTON BEACH, California and AMSTERDAM, December 12 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van 't Veer, from the Netherlands Cancer Inst...

Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects

RIVERSIDE, Calif., Nov. 20 /PRNewswire/ -- Milk. It does a body good. And now it's doing it even better than originally thought. After years of research, scientists at OncoNutrition(TM) have discovered peptides found in cow's milk that stimulate the body's own production of antioxidants. ...

Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

SEATTLE, Nov. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Clinical Cancer Research has published in the November 1, 2008 issue the results of a study authored by Samual Jacobs et al. investigating the use of short-course CHOP-R followe...

Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium

SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City. The presentation, whi...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

- Voreloxin Demonstrates Promising Clinical Activity in Patients with Difficult-to-Treat Cancers - SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) presented data from three clinical trials of the company's lead ...

Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting

PARIS, October 24 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of five posters at the joint...

Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebsel...

Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)

CHICAGO, June 25 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced that...

New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)

BETHLEHEM, Pa., June 23 /PRNewswire/ -- A new blood test may make it easier for oncologists to accurately measure and personalize 5-fluorouracil (5-FU) dosing for patients undergoing continuous infusion chemotherapy regimens. Data from a multicenter trial showed that a nanoparticle-based immun...

Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation

Case is first to show safety and effectiveness of using cloned cells alone to kill tumors SEATTLE, June 18 /PRNewswire/ -- Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced soli...

Saladax Biomedical's 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU

BETHLEHEM, Pa., June 17 /PRNewswire/ -- Saladax Biomedical, a company specializing in chemotherapy therapeutic drug monitoring, today announced CE mark registration in the European Union (EU) for its 5-FU Personalized Chemotherapy Management (PCM(R)) assay on the Olympus AU400 Clinical Chemist...

Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma

Updated Clinical Phase 2 data presented at American Society of Clinical Oncology Annual Meeting PRINCETON, N.J., June 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced updated long-term follow-up and overall survival (OS) results from a Phase 2 c...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

Related Clinical Study Shows Potential Utility of Short-Course High-Dose Therapy BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced preliminary results that have shown a high objective response rate in...

Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer

MARSEILLE, France, May 19 /PRNewswire/ -- IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced today that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will ...

Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer

BETHLEHEM, Pa., May 2 /PRNewswire/ -- Can a blood test improve treatment outcomes for colorectal cancer patients? Recently published studies indicate that personalized chemotherapy dose management -- measuring drug levels in patients' blood and adjusting them for optimal dosing -- can substant...

Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells

SAN DIEGO, April 13 /PRNewswire-USNewswire/ -- Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit today presented findings showing that adding curcumin or resveratrol to conventional chemotherapy could be effective in preventing the growth of chemo-resistant colon cancer cel...

Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia

OSAKA, Japan and PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) and Affymax, Inc. (Nasdaq: AFFY ) today announced that Takeda has dosed the first patient in the United States in a clinical trial of the investigational new drug, Hematide(...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

Phase II Investigational Trial Published in CANCER: the Journal of the American Cancer Society SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) announced today that results of a phase II clinical study, published in the jou...

Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma

Results underscore promise of radioimmunotherapy in ASCT and warrant randomized trial SEATTLE, Jan. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that results of a phase II clinical study, published in the Journa...

Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission

Updated Phase 3 Results Released at American Society of Hematology Meeting BERKELEY HEIGHTS, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA ) announced the release of new survival analyses based upon extended follow-up of patients in the Company's randomized Phase 3 t...

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1 Data Showing No Evidence of Increased Toxicity When Combined with Sorafenib NEW YORK, Nov. ...

Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents

SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain s...

Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study

ANN ARBOR, Mich., Sept. 18 /PRNewswire-FirstCall/ -- In a study published by the Journal of Supportive Care in Cancer, researchers from Thomson Healthcare found that when cancer patients used a handheld computer before office visits to rate and report their pain, fatigue, and depression, docto...

EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer

LYON, France, Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm...

EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer

LYON, France, Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm...

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

BOSTON, Oct. 26 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced positive Phase 2 data for the Company's lead antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC). The Phase 2 study compared safety and efficacy of oral and intravenous (IV) forms of PTK 0796 to Zyvox(R) ...

Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

BOSTON, Oct. 14 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, amadacycline, formerly PTK 0796, a first-in-class aminomethylcycline, will be the subject of a Late Breaker poster presentation at the 48th Interscience Conference on Antimicrobial Agents ...

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

Quark siRNAs Examined Alone and in Combination with Chemotherapy FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cance...

F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy

Patch Provides Five Days of Continuous Control for Highly Feared Side Effect of Chemotherapy Expert Urges "Zero Tolerance" to Avoid Missed Treatments BEDMINSTER, N.J., Sept. 15 /PRNewswire-FirstCall/ -- ProStrakan Group plc (LSE: PSK) today announced the U.S. Fo...

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy

Interim data from Phase 1b Study indicate that adecatumumab in combination with docetaxel is safe and well tolerated and suggest a better outcome for breast cancer patients with high EpCAM expression BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a...

Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy

First Phase III study performed solely in high risk node-negative population to show significant improvement in Disease Free Survival (DFS) BRIDGEWATER, N.J., May 27 /PRNewswire-FirstCall/ -- Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced today that ...

Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy

- Results of first reported clinical trial of any antibody to TRAIL receptor 2 in combination with chemotherapy, presented at AACR-NCI-EORTC International Conference - - Preclinical study demonstrating synergy of TRAIL receptor antibodies with chemotherapy highlighted ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

CHICAGO, Sept. 20 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS ), presented further data in support of cethromycin, the Company's lead compound, at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, September 17 - 20. A total...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

CHICAGO, Sept. 20 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS ), presented further data in support of cethromycin, the Company's lead compound, at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, September 17 - 20. A total...